ReviewSignal transduction and targeted therapy2026
Cell differentiation-related signaling pathways: biological functions, diseases and therapeutic targets.
Review in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell differentiation, the process by which stem cells acquire specialized functions, underpins embryonic development, tissue homeostasis, and regeneration. This process is governed by evolutionarily conserved signaling pathways, including Wnt, Notch, Hedgehog, TGF-β, and Hippo, which integrate extracellular cues with intrinsic genetic programs to determine cell fate. Here, we provide a comprehensive overview of the molecular architecture of these pathways, spanning ligand-receptor interactions to downstream transcriptional regulation. We further highlight multilayered regulatory mechanisms such as epigenetic modifications, non-coding RNAs, feedback loops, and pathway crosstalk that fine-tune signaling outputs to ensure spatiotemporal precision in fate decisions. We also discuss how tissue-specific contexts and interactions among these pathways generate distinct differentiation outcomes in different organs and disease settings. Dysregulation of these networks contributes to diverse pathological states, driving uncontrolled proliferation in cancer, maladaptive remodeling in cardiovascular disease, neuronal loss in neurodegeneration, metabolic imbalance, digestive dysfunction, chronic inflammation in respiratory and autoimmune diseases, and skeletal disorders. Reflecting their clinical importance, we also summarize recent therapeutic advances, including small-molecule inhibitors, monoclonal antibodies, gene-based strategies, and pathway-modulating compounds, which target these pathways to restore normal cellular function. Particular attention is given to distinguishing preclinical findings from clinical applications and to the translational challenges of pathway-targeted therapies. Collectively, this review underscores the central role of differentiation-related signaling in health and disease and highlights emerging opportunities for therapeutic intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.